Factor VIII, recombinant human: Drug information

For additional information see "Factor VIII, recombinant human: Patient drug information" and "Factor VIII, recombinant human: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table

Brand Names: US

Advate;
Afstyla;
Kogenate FS;
Kovaltry;
Novoeight;
Nuwiq;
Recombinate;
Xyntha;
Xyntha Solofuse

Brand Names: Canada

Advate [DSC];
Kovaltry;
Nuwiq;
Xyntha;
Xyntha Solofuse;
Zonovate

Pharmacologic Category

Antihemophilic Agent

Dosing: Adult

Hemophilia A, treatment and control of bleeding episodes in patients receiving fitusiran

Hemophilia A, treatment and control of bleeding episodes in patients receiving fitusiran:

During first 7 days of fitusiran initiation:

IV: Manage bleeding with patient’s previously established regimen of clotting factor concentrate or bypassing agent (Ref).

After 7 days from first fitusiran dose:

IV: Initial: 10 to 20 units/kg; reassess clinical status and need for repeat doses; in general, dose should not be repeated within 24 hours. Higher doses or more frequent administration may be considered based on clinical judgment (Ref).

Hemophilia A, without inhibitors

Hemophilia A, without inhibitors:

Treatment and control of bleeding episodes or perioperative management (when baseline factor VIII level is known):

Intermittent IV bolus dosing: IV: Utilize steps 1 to 3 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL (Ref).

Step 1: Determine desired factor VIII peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower-dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.

Note: For patients without inhibitors and receiving emicizumab who experience breakthrough bleeding, antihemophilic factor should be dosed to target the desired peak factor VIII levels outlined in the table as emicizumab is not indicated for treatment of bleeding episodes.

**Antihemophilic Factor (Recombinant) WFH Treatment Recommendations^d**
Type of hemorrhage or surgery	Lower-dose practice pattern		Higher-dose practice pattern
Type of hemorrhage or surgery	Desired peak factor VIII level	Treatment duration	Desired peak factor VIII level	Treatment duration
^aMay be longer if response is inadequate.
^bSometimes longer as secondary prophylaxis during physical therapy.
^cA single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.
^dWFH [Srivastava 2020].
Joint	10 to 20 units/dL	1 to 2 days^a,c	40 to 60 units/dL	1 to 2 days^a,c
Superficial muscle/no neurovascular compromise (except iliopsoas)	10 to 20 units/dL	2 to 3 days^a	40 to 60 units/dL	2 to 3 days^a
Iliopsoas or deep muscle with neurovascular injury or substantial blood loss:
Initial	20 to 40 units/dL	1 to 2 days	80 to 100 units/dL	1 to 2 days
Maintenance	10 to 20 units/dL	3 to 5 days^b	30 to 60 units/dL	3 to 5 days^b
Intracranial:
Initial	50 to 80 units/dL	1 to 3 days	80 to 100 units/dL	1 to 7 days
Maintenance	30 to 50 units/dL	4 to 7 days	50 units/dL	8 to 21 days
Maintenance	20 to 40 units/dL	8 to 14 days	-	-
Throat and neck:
Initial	30 to 50 units/dL	1 to 3 days	80 to 100 units/dL	1 to 7 days
Maintenance	10 to 20 units/dL	4 to 7 days	50 units/dL	8 to 14 days
Gastrointestinal:
Initial	30 to 50 units/dL	1 to 3 days	80 to 100 units/dL	7 to 14 days
Maintenance	10 to 20 units/dL	4 to 7 days	50 units/dL	-
Renal	20 to 40 units/dL	3 to 5 days	50 units/dL	3 to 5 days
Deep laceration	20 to 40 units/dL	5 to 7 days	50 units/dL	5 to 7 days
Surgery (major):
Preop	60 to 80 units/dL	-	80 to 100 units/dL	-
Postop	30 to 40 units/dL	1 to 3 days	60 to 80 units/dL	1 to 3 days
	20 to 30 units/dL	4 to 6 days	40 to 60 units/dL	4 to 6 days
	10 to 20 units/dL	7 to 14 days	30 to 50 units/dL	7 to 14 days
Surgery (minor):
Preop	40 to 80 units/dL	-	50 to 80 units/dL	-
Postop	20 to 50 units/dL	1 to 5 days	30 to 80 units/dL	1 to 5 days

Step 2: Calculate dose using desired peak factor VIII level from step 1 and the following equation:

Factor VIII units required = [(desired peak factor VIII level − patient's baseline factor VIII level) × body weight (kg)]/2

Note: Factor VIII level units are units/dL.

Example for 50 kg patient with desired peak factor VIII level of 35 units/dL and baseline factor VIII level of 5 units/dL:

Factor VIII units required = [(35 units/dL − 5 units/dL) × 50 kg]/2 = 750 units of factor VIII

Step 3: Determine need for repeat dosing based on manufacturer's recommended frequency of repeat dosing. Note: Frequency of administration must also take into consideration subsequent factor VIII activity measurements and the clinical response.

**Antihemophilic Factor (Recombinant) Administration Frequency According to Clinical Scenario**
Product	Bleeding event			Surgery
Product	Minor severity	Moderate severity	Major severity	Minor bleeding risk	Major bleeding risk
Advate	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours
Afstyla	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 24 hours	Every 8 to 24 hours
Kogenate FS	Repeat × 1 if evidence of further bleeding	Every 12 to 24 hours	Every 8 to 12 hours	Every 12 to 24 hours	Every 6 to 12 hours
Kovaltry	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 24 hours	Every 8 to 24 hours
Novoeight	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 24 hours	Every 8 to 24 hours
Nuwiq	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 24 hours	Every 8 to 24 hours
Recombinate	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	A single dose typically adequate	Every 8 to 24 hours
Xyntha/Xyntha Solofuse	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours
Zonovate (Canadian product)	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 24 hours	Every 8 to 24 hours

Continuous infusion dosing (Ref):

Note: Continuous infusion administration is preferred over intermittent bolus administration for patients requiring prolonged treatment courses (eg, postoperative management after surgery with major bleeding risk). To ensure safe and effective use, only products with extended stability information should be used. Extended stability information may not be available for all products; contact product manufacturer to obtain current recommendations. Use of a smart infusion pump with small volume infusion capability is also necessary.

IV: Administer an initial bolus to achieve the desired factor VIII level (see steps 1 and 2 under intermittent bolus dosing), then initiate continuous infusion at 2 to 4 units/kg/hour. Adjust dose based on frequent factor assays (at least daily) and calculation of factor VIII clearance at steady-state using the below equations.

Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (measured factor VIII level in units/mL)

New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) x (desired factor VIII level in units/mL)

Note: With infusion dose increases, re-bolus should be considered to achieve target factor VIII level more quickly. See steps 1 and 2 under intermittent bolus dosing to determine re-bolus dose.

Treatment and control of bleeding episodes (when baseline factor VIII level is not known):

Note: After the loading dose, if possible, it is preferred to obtain a factor VIII level to determine subsequent doses based on patient needs rather than continuing an empiric dosing regimen. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL (Ref). Consider transfer of care to comprehensive hemophilia treatment center with capacity to perform clotting factor assays and inhibitor testing. For patients without inhibitors and receiving emicizumab who experience breakthrough bleeding, antihemophilic factor should be dosed to target the desired peak factor VIII level as emicizumab is not indicated for treatment of bleeding episodes (Ref).

**Antihemophilic Factor (Recombinant) D** **ose and** **Frequency According to Clinical Scenario^a**
Product and bleeding severity	Loading dose, IV	Desired peak factor VIII level^b	Maintenance dose^b, IV	Frequency of maintenance dose^b	Treatment duration^c
^aManufacturer’s labeling.
^bDesired peak factor VIII level, dose, and frequency of maintenance dose administration may change as bleeding becomes more controlled. Individualize dosing to patient-specific needs by evaluating circulating factor VIII levels.
^c Dosing continues until bleeding resolves and may extend beyond what is indicated in this table. It is preferable to individualize dosing based on patient-specific needs by evaluating circulating factor VIII levels.
^dNational Bleeding Disorders Foundation, Medical and Scientific Advisory Council of the National Hemophilia Foundation, document #257.
^eApproximate dose based on estimated incremental recovery of 2 units/dL (manufacturer’s labeling).
Advate
Minor bleeding	10 to 20 units/kg	20 to 40 units/dL	10 to 20 units/kg	Every 12 to 24 hours	1 to 3 days
Moderate bleeding	15 to 30 units/kg	30 to 60 units/dL	15 to 30 units/kg	Every 12 to 24 hours	≥3 days
Major bleeding	50 units/kg^d	80 to 100 units/dL^d	30 to 50 units/kg	Every 8 to 24 hours	Not specified
Afstyla
Minor bleeding	10 to 20 units/kg^e	20 to 40 units/dL	10 to 20 units/kg^e	Every 12 to 24 hours	Not specified
Moderate bleeding	15 to 30 units/kg^e	30 to 60 units/dL	15 to 30 units/kg^e	Every 12 to 24 hours	Not specified
Major bleeding	50 units/kg^d	80 to 100 units/dL^d	30 to 50 units/kg^e	Every 8 to 24 hours	Not specified
Kogenate FS
Minor bleeding	10 to 20 units/kg	20 to 40 units/dL	10 to 20 units/kg	Repeat if evidence of bleeding	Not specified
Moderate bleeding	15 to 30 units/kg	30 to 60 units/dL	15 to 30 units/kg	Every 12 to 24 hours	Not specified
Major bleeding	50 units/kg^d	80 to 100 units/dL^d	20 to 25 units/kg	Every 8 to 12 hours	Not specified
Kovaltry
Minor bleeding	10 to 20 units/kg^e	20 to 40 units/dL	10 to 20 units/kg^e	Every 12 to 24 hours	At least 1 day
Moderate bleeding	15 to 30 units/kg^e	30 to 60 units/dL	15 to 30 units/kg^e	Every 12 to 24 hours	3 to 4 days
Major bleeding	50 units/kg^d	80 to 100 units/dL^d	30 to 50 units/kg^e	Every 8 to 24 hours	Not specified
Novoeight
Minor bleeding	10 to 20 units/kg^e	20 to 40 units/dL	10 to 20 units/kg^e	Every 12 to 24 hours	At least 1 day
Moderate bleeding	15 to 30 units/kg^e	30 to 60 units/dL	15 to 30 units/kg^e	Every 12 to 24 hours	3 to 4 days
Major bleeding	50 units/kg^d	80 to 100 units/dL^d	30 to 50 units/kg^e	Every 8 to 24 hours	7 to 10 days
Nuwiq
Minor bleeding	10 to 20 units/kg^e	20 to 40 units/dL	10 to 20 units/kg^e	Every 12 to 24 hours	At least 1 day
Moderate bleeding	15 to 30 units/kg^e	30 to 60 units/dL	15 to 30 units/kg^e	Every 12 to 24 hours	3 to 4 days
Major bleeding	50 units/kg^d	80 to 100 units/dL^d	30 to 50 units/kg^e	Every 8 to 24 hours	Not specified
Recombinate
Minor bleeding	10 to 20 units/kg^e	20 to 40 units/dL	10 to 20 units/kg^e	Every 12 to 24 hours	1 to 3 days
Moderate bleeding	15 to 30 units/kg^e	30 to 60 units/dL	15 to 30 units/kg^e	Every 12 to 24 hours	≥3 days
Major bleeding	50 units/kg^d	80 to 100 units/dL^d	30 to 50 units/kg^e	Every 8 to 24 hours	Not specified
Xyntha/Xyntha Solofuse
Minor bleeding	10 to 20 units/kg^e	20 to 40 units/dL	10 to 20 units/kg^e	Every 12 to 24 hours	At least 1 day
Moderate bleeding	15 to 30 units/kg^e	30 to 60 units/dL	15 to 30 units/kg^e	Every 12 to 24 hours	3 to 4 days
Major bleeding	50 units/kg^d	80 to 100 units/dL^d	30 to 50 units/kg^e	Every 8 to 24 hours	Not specified
Zonovate (Canadian product)
Minor bleeding	10 to 20 units/kg^e	20 to 40 units/dL	10 to 20 units/kg^e	Every 12 to 24 hours	At least 1 day
Moderate bleeding	15 to 30 units/kg^e	30 to 60 units/dL	15 to 30 units/kg^e	Every 12 to 24 hours	3 to 4 days
Major bleeding	50 units/kg^d	80 to 100 units/dL^d	30 to 50 units/kg^e	Every 8 to 24 hours	Not specified

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes:

Note: Preferably, dosing should be tailored to ensure trough factor VIII levels of at least 1% and ideally ≥3 to 5% are achieved, but prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (Ref).

Advate: IV: 20 to 40 units/kg every other day (3 to 4 times weekly). Alternatively, an every-third-day dosing regimen may be used to target factor VIII trough levels of ≥1%.

Afstyla: IV: 20 to 50 units/kg 2 to 3 times weekly.

Kogenate FS: IV: 25 units/kg 3 times weekly.

Kovaltry: IV: 20 to 40 units/kg 2 or 3 times weekly.

Novoeight: IV: 20 to 50 units/kg 3 times weekly or 20 to 40 units/kg every other day.

Nuwiq: IV: 30 to 40 units/kg every other day.

Xyntha/Xyntha Solofuse: IV: 30 units/kg 3 times weekly.

Zonovate [Canadian product]: IV: 20 to 50 units/kg 3 times weekly or 20 to 40 units/kg every other day.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Obesity: Adult

There are insufficient data to recommend the best dosing weight to use in patients with obesity. Dose adjustments should ultimately be made based on individual patient response to therapy. Due to the paucity of data, refer to institutional protocols. Refer to adult dosing for indication-specific dosing.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Factor VIII, recombinant human: Pediatric drug information")

Hemophilia A

Hemophilia A: Individualize dosage based on clinical response and factor VIII activity evaluated at baseline and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2% of normal. Patients with inhibitory antibodies to factor VIII may require higher doses, more frequent administration, and/or selection of alternative therapy.

Treatment and control of bleeding episodes or perioperative management: Note: Dosage is expressed in units of factor VIII activity and must be individualized based on formulation, severity of factor VIII deficiency, extent and location of bleed, individualized incremental recovery using factor VIII activity assays, and clinical situation of patient. Ages vary by product; see product-specific labeling for approved ages.

Infants, Children, and Adolescents: IV:

Intermittent IV bolus dosing: Utilize steps 1 through 3 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL (Ref).

Step 1: Determine desired factor VIII peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. These recommendations reflect WFH guidelines for higher-dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels (if available) before the next dose (Ref).

**WFH Treatment Recommendations^a**
Site of hemorrhage/Clinical situation	Desired factor VIII peak level	Duration^b
^aWFH = World Federation of Hemophilia (Ref).
^bDepending on procedure; the number of doses would depend on the half-life of the clotting factor concentrate used.
^c May be longer if response is inadequate.
^d A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.
^e Sometimes longer as secondary prophylaxis during physical therapy.
Joint	40 to 60 units/dL	1 to 2 days^c,d
Superficial muscle/no neurovascular compromise	40 to 60 units/dL	2 to 3 days^c
Iliopsoas or deep muscle with neurovascular injury, or substantial blood loss	Initial: 80 to 100 units/dL	1 to 2 days
	Maintenance: 30 to 60 units/dL	3 to 5 days^e
CNS/Head	Initial: 80 to 100 units/dL	1 to 7 days
CNS/Head	Maintenance: 50 units/dL	8 to 21 days
Throat and neck	Initial: 80 to 100 units/dL	1 to 7 days
Throat and neck	Maintenance: 50 units/dL	8 to 14 days
Gastrointestinal	Initial: 80 to 100 units/dL	7 to 14 days
Gastrointestinal	Maintenance: 50 units/dL	Not specified
Renal	50 units/dL	3 to 5 days
Deep laceration	50 units/dL	5 to 7 days
Surgery (major)	Preop: 80 to 100 units/dL	Single dose
	Postop: 60 to 80 units/dL	1 to 3 days
	Postop: 40 to 60 units/dL	4 to 6 days
	Postop: 30 to 50 units/dL	7 to 14 days
Surgery (minor)	Preop: 50 to 80 units/dL	Single dose
Surgery (minor)	Postop: 30 to 80 units/dL	1 to 5 days

Step 2: Calculate dose using desired peak factor VIII level from step 1 and the following equation:

Formula for units required to raise blood level:

Factor VIII units required = [(desired peak factor VIII level − baseline factor VIII level) × body weight (kg)]/2

Example for 25 kg patient with a desired peak factor VIII level of 35 units/dL and baseline factor VIII level of 5 units/dL:

Factor VIII units required = [(35 units/dL − 5 units/dL) × 25 kg]/2 = 375 units of factor VIII

Step 3: Determine the frequency of repeat dosing based on half-life of product used (see product-specific labeling for details), type of bleed or surgery, and patient response. If subsequent factor VIII levels are available for individual patients, these should be taken into consideration when determining the frequency of repeat dose.

**Antihemophilic Factor (Recombinant) Administration Frequency According to Clinical Scenario**
Product	Type of bleeding event			Type of surgery
Product	Minor severity^a	Moderate severity^b	Major severity^c	Minor bleeding risk^d	Major bleeding risk^e
^a Minor bleeds include early hemarthrosis, mild muscle bleeding, or mild oral bleeding episode.
^b Moderate bleeds include muscle bleeding, moderate bleeding into the oral cavity, definite hemarthroses, and known trauma.
^c Major bleeds include significant GI bleeding; intracranial, intra-abdominal, or intrathoracic bleeding; CNS bleeding; bleeding in the retropharyngeal or retroperitoneal spaces or iliopsoas sheath; fractures; head trauma.
^d Including tooth extraction.
^e For example: Intracranial, intra-abdominal, or intrathoracic surgery; joint replacement surgery.
Advate	Infants and Children <6 years: Every 8 to 24 hours	Infants and Children <6 years: Every 8 to 24 hours	Infants and Children <6 years: Every 6 to 12 hours	Infants, Children, and Adolescents: Every 12 to 24 hours	Infants and Children <6 years: Every 6 to 24 hours
Advate	Children ≥6 years and Adolescents: Every 12 to 24 hours	Children ≥6 years and Adolescents: Every 12 to 24 hours	Children ≥6 years and Adolescents: Every 8 to 24 hours	Infants, Children, and Adolescents: Every 12 to 24 hours	Children ≥6 years and Adolescents: Every 8 to 24 hours
Afstyla	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 24 hours	Every 8 to 24 hours
Kogenate FS	Repeat × 1 if evidence of further bleeding	Every 12 to 24 hours	Every 8 to 12 hours	Every 12 to 24 hours	Every 6 to 12 hours
Kovaltry	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 24 hours	Every 8 to 24 hours
Novoeight	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 24 hours	Every 8 to 24 hours
Nuwiq	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 24 hours	Every 8 to 24 hours
Recombinate	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	A single dose is typically adequate	Every 8 to 24 hours
Xyntha/Xyntha Solofuse	Every 12 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours	Every 12 to 24 hours	Every 8 to 24 hours

Continuous IV infusion dosing: Limited data available (Ref):

Note: Continuous infusion administration is preferred over intermittent bolus administration for patients requiring prolonged treatment courses (eg, postoperative management after surgery with major bleeding risk) to avoid peaks and troughs associated with intermittent infusions. To ensure safe and effective use, only products with extended stability information should be used. Extended stability information may not be available for all products; contact product manufacturer to obtain current recommendations. Use of a smart infusion pump with small volume infusion capability is also necessary. In general, administration of factor VIII 4 units/kg/hour will increase circulating factor VIII levels by 1 unit/mL.

Infants, Children, and Adolescents: Continuous IV infusion: Note: Use with caution and consider risk vs benefit in patients with <20 exposure days or mild hemophilia due to increased risk of inhibitor development (Ref).

Following initial bolus to achieve the desired factor VIII level (see steps 1 and 2 under intermittent bolus dosing): Initial dosing: 2 to 4 units/kg/hour; adjust dose based on frequent factor VIII assays and calculation of factor VIII clearance at steady state using the following equations (Ref):

Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) / (measured factor VIII level in units/mL)

New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) × (desired factor VIII level in units/mL)

Note: With infusion dose increases, re-bolus should be considered to achieve target factor VIII level more quickly. See steps 1 and 2 under intermittent bolus dosing to determine re-bolus dose.

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes:

Note: Dose should be individualized; dose intensity should take into account disease severity, patient's activity and lifestyle, and pharmacokinetic properties of product, and should be adjusted if breakthrough bleeding occurs. See guidelines for in-depth discussion of risks and benefits of each approach (Ref).

Infants, Children, and Adolescents:

High dose: IV: 25 to 40 units/kg/dose every 2 days.

Intermediate dose: IV: 15 to 25 units/kg/dose 3 times weekly.

Low dose: IV: 10 to 15 units/kg/dose 2 to 3 times weekly. Note: Low-dose prophylaxis may be used in young patients as initial therapy to allow patients and families to gradually adjust to prophylaxis and improve adherence; close monitoring is required since patients are at a higher risk for bleeding until escalation occurs.

Breakthrough bleeding, treatment in patients with hemophilia A receiving fitusiran

Breakthrough bleeding, treatment in patients with hemophilia A receiving fitusiran:

Note: Antihemophilic factor (recombinant) doses provided below are recommended for breakthrough bleeding in patients who are receiving fitusiran; higher doses may be associated with increased risk of thrombotic events (Ref).

Children ≥12 years and Adolescents:

During the first 7 days of fitusiran initiation: IV: Manage bleeding with patient's previously established antihemophilic factor (recombinant) regimen (Ref).

More than 7 days from first fitusiran dose: IV: Initial: 10 units/kg/dose; repeat dose may be considered after 24 hours if indicated. Higher doses or more frequent administration may be considered based on clinical judgment (weigh risks of thrombosis vs benefits); maximum dose: 20 units/kg (Ref).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Actual frequency may vary by product and population. Reported adverse reactions are for adults and pediatrics.

>10%:

Dermatologic: Pruritus (≤16%), skin rash (≤16%), urticaria (≤16%)

Hematologic & oncologic: Increased factor VIII inhibitors (previously untreated patients/minimally treated patients: 50% to 55%; previously treated patients: <1%; may include neutralizing antibodies)

Nervous system: Headache (9% to 24%)

Neuromuscular & skeletal: Arthralgia (5% to 23%)

Respiratory: Cough (10% to 13%), nasopharyngitis (12%), upper respiratory tract infection (7% to 22%)

Miscellaneous: Fever (9%; previously untreated patients/minimally treated patients: 30%; previously treated patents: 4%)

1% to 10%:

Gastrointestinal: Abdominal distress (1%), abdominal pain (4%), diarrhea (5% to 8%), dyspepsia (2%), vomiting (3% to 8%)

Hypersensitivity: Hypersensitivity reaction (≤2%)

Infection: Varicella zoster infection (4%)

Local: Infusion-site reaction (4% to 7%), injection-site reaction (1% to 3%)

Nervous system: Asthenia (6%), chills (≤7%), dizziness (≤2%), insomnia (1% to 2%), malaise (1%), procedural pain (5%)

Neuromuscular & skeletal: Back pain (4%), limb injury (6%), limb pain (≤4%)

Otic:Otic infection (≤5%)

Respiratory: Dyspnea (1%), lower respiratory tract infection (8%), nasal congestion (6%), pharyngitis (5%), pharyngolaryngeal pain (5%), rhinitis (8%)

<1%:

Cardiovascular: Chest discomfort, cold extremity, flushing, hypotension, palpitations, sinus tachycardia, syncope

Dermatologic: Allergic dermatitis, erythema of skin, hyperhidrosis, maculopapular rash, pallor

Gastrointestinal: Dysgeusia, nausea

Hematologic & oncologic: Hematoma, lymphadenopathy

Local: Inflammation at injection site, pain at injection site

Nervous system: Fatigue, feeling hot, neurological deterioration, paresthesia, tremor

Renal: Renal neoplasm (benign)

Respiratory: Epistaxis

Frequency not defined: Endocrine & metabolic: Hot flash

Postmarketing:

Cardiovascular: Chest pain, tachycardia

Hypersensitivity: Anaphylaxis, angioedema, facial edema

Nervous system: Loss of consciousness, restlessness

Respiratory: Cyanosis, laryngeal edema

Contraindications

Hypersensitivity (eg, anaphylaxis) to antihemophilic factor, mouse or hamster protein (Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Recombinate, Xyntha, Zonovate [Canadian product]), bovine protein (Recombinate only), or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Antibody formation: The development of factor VIII antibodies has been reported with antihemophilic factors; monitor for signs of formation of antibodies to factor VIII; may occur at any time but more common in young children with severe hemophilia and previously untreated patients. Suspect factor VIII antibodies if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration.

• Hypersensitivity reactions: Allergic hypersensitivity reactions (including anaphylaxis) may occur; discontinue if hypersensitivity symptoms occur and administer appropriate treatment.

Dosage form specific issues:

• Albumin: Recombinate is stabilized using human albumin.

• Bovine: Recombinate may contain bovine protein.

• Mouse/hamster protein: Some products may contain trace amounts of mouse or hamster protein.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

• Sucrose: Some products are stabilized with or may contain sucrose.

• von Willebrand factor: Some products contain naturally-occurring von Willebrand factor for stabilization; however, efficacy has not been established for the treatment of von Willebrand disease.

Other warnings/precautions:

• Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.

Warnings: Additional Pediatric Considerations

Allergic-type hypersensitivity reactions including anaphylaxis may occur; discontinue therapy immediately if urticaria, hives, hypotension, tightness of the chest, wheezing, or anaphylaxis develop; emergency treatment and resuscitative measures (eg, epinephrine, oxygen) may be needed. Clinical response to antihemophilic factor administration may vary; dosage must be individualized based on coagulation studies (performed prior to treatment and at regular intervals during treatment) and clinical response. If bleeding is not controlled with the recommended dose, determine plasma level of factor VIII and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor VIII fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate. Formation of factor VIII inhibitors (neutralizing antibodies to AHF recombinant) may occur at any time, but is more common in young children with severe hemophilia during the first years of therapy, or in patients at any age who received little prior therapy with factor VIII; monitor patients appropriately.

Dosage Forms Considerations

Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Kit, Intravenous:

Kogenate FS: 250 units, 500 units, 1000 units

Kit, Intravenous [preservative free]:

Afstyla: 250 units, 500 units, 1000 units, 1500 units, 2000 units, 2500 units, 3000 units [contains polysorbate 80]

Kogenate FS: 2000 units, 3000 units

Nuwiq: 250 units, 500 units, 1000 units, 2000 units, 2500 units, 3000 units, 4000 units

Xyntha: 250 units, 500 units, 1000 units, 2000 units [albumin free; contains polysorbate 80]

Xyntha Solofuse: 250 units, 500 units, 1000 units, 2000 units, 3000 units [albumin free; contains polysorbate 80]

Solution Reconstituted, Intravenous:

Kovaltry: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]

Solution Reconstituted, Intravenous [preservative free]:

Advate: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea); 4000 units (1 ea) [albumin free; contains polysorbate 80]

Novoeight: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]

Nuwiq: 1500 units (1 ea) [latex free]

Nuwiq: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 2500 units (1 ea); 3000 units (1 ea); 4000 units (1 ea)

Recombinate: 220-400 units (1 ea); 401-800 units (1 ea); 801-1240 units (1 ea); 1241-1800 units (1 ea); 1801-2400 units (1 ea) [contains albumin human, polyethylene glycol (macrogol), polysorbate 80]

Generic Equivalent Available: US

Pricing: US

Kit (Afstyla Intravenous)

250 unit (Price provided is per AHF Unit): $2.35

500 unit (Price provided is per AHF Unit): $2.35

1000 unit (Price provided is per AHF Unit): $2.35

1500 unit (Price provided is per AHF Unit): $2.35

2000 unit (Price provided is per AHF Unit): $2.35

2500 unit (Price provided is per AHF Unit): $2.35

3000 unit (Price provided is per AHF Unit): $2.35

Kit (Kogenate FS Intravenous)

250 unit (Price provided is per AHF Unit): $2.42

500 unit (Price provided is per AHF Unit): $2.42

1000 unit (Price provided is per AHF Unit): $2.42

2000 unit (Price provided is per AHF Unit): $2.42

3000 unit (Price provided is per AHF Unit): $2.42

Kit (Nuwiq Intravenous)

250 unit (Price provided is per AHF Unit): $2.28

500 unit (Price provided is per AHF Unit): $2.28

1000 unit (Price provided is per AHF Unit): $2.28

2000 unit (Price provided is per AHF Unit): $2.28

2500 unit (Price provided is per AHF Unit): $2.28

3000 unit (Price provided is per AHF Unit): $2.28

4000 unit (Price provided is per AHF Unit): $2.28

Kit (Xyntha Intravenous)

250 unit (Price provided is per AHF Unit): $2.29

500 unit (Price provided is per AHF Unit): $2.29

1000 unit (Price provided is per AHF Unit): $2.29

2000 unit (Price provided is per AHF Unit): $2.29

Kit (Xyntha Solofuse Intravenous)

250 unit (Price provided is per AHF Unit): $2.29

500 unit (Price provided is per AHF Unit): $2.29

1000 unit (Price provided is per AHF Unit): $2.29

2000 unit (Price provided is per AHF Unit): $2.29

3000 unit (Price provided is per AHF Unit): $2.29

Solution (reconstituted) (Advate Intravenous)

250 unit (Price provided is per AHF Unit): $2.35

500 unit (Price provided is per AHF Unit): $2.35

1000 unit (Price provided is per AHF Unit): $2.35

1500 unit (Price provided is per AHF Unit): $2.35

2000 unit (Price provided is per AHF Unit): $2.35

3000 unit (Price provided is per AHF Unit): $2.35

4000 unit (Price provided is per AHF Unit): $2.35

Solution (reconstituted) (Kovaltry Intravenous)

250 unit (Price provided is per AHF Unit): $2.89

250 unit (per each): $2.89

500 unit (Price provided is per AHF Unit): $2.89

500 unit (per each): $2.89

1000 unit (per each): $2.89

2000 unit (per each): $2.89

3000 unit (per each): $2.89

Solution (reconstituted) (Novoeight Intravenous)

250 unit (Price provided is per AHF Unit): $2.71

500 unit (Price provided is per AHF Unit): $2.71

1000 unit (Price provided is per AHF Unit): $2.71

1500 unit (Price provided is per AHF Unit): $2.71

2000 unit (Price provided is per AHF Unit): $2.71

3000 unit (Price provided is per AHF Unit): $2.71

Solution (reconstituted) (Nuwiq Intravenous)

250 unit (Price provided is per AHF Unit): $2.28

500 unit (Price provided is per AHF Unit): $2.28

1000 unit (Price provided is per AHF Unit): $2.28

1500 unit (Price provided is per AHF Unit): $2.28

2000 unit (Price provided is per AHF Unit): $2.28

2500 unit (Price provided is per AHF Unit): $2.28

3000 unit (Price provided is per AHF Unit): $2.28

4000 unit (Price provided is per AHF Unit): $2.28

Solution (reconstituted) (Recombinate Intravenous)

220-400 unit (Price provided is per AHF Unit): $2.35

401-800 unit (Price provided is per AHF Unit): $2.35

801-1240 unit (Price provided is per AHF Unit): $2.35

1241-1800 unit (Price provided is per AHF Unit): $2.35

1801-2400 unit (Price provided is per AHF Unit): $2.35

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Kit, Intravenous:

Xyntha: 250 units, 500 units [contains polysorbate 80]

Xyntha Solofuse: 500 units, 1000 units, 2000 units, 3000 units [contains polysorbate 80]

Solution Reconstituted, Intravenous:

Advate: 250 units ([DSC]); 500 units ([DSC]); 1000 units ([DSC]); 1500 units ([DSC]); 2000 units ([DSC]); 3000 units ([DSC]) [contains polysorbate 80]

Kovaltry: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]

Nuwiq: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea); 4000 units (1 ea)

Zonovate: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]

Administration: Adult

IV: Rate of administration should be determined by patient tolerability (maximum rates vary by product).

Advate: Infuse over ≤5 minutes (maximum: 10 mL/minute)

Afstyla: Infuse up to a maximum rate of 10 mL/minute

Kogenate FS, Kovaltry: Infuse over 1 to 15 minutes

Novoeight: Infuse slowly over 2 to 5 minutes

Nuwiq: Infuse up to a maximum rate of 4 mL/minute

Recombinate: Infuse up to a maximum rate of 5 mL/minute

Xyntha, Xyntha Solofuse: Infuse over several minutes. Do not admix or administer in same tubing as other medications.

Zonovate [Canadian product]: Infuse at a rate of 1 to 2 mL/minute.

Continuous infusion (off-label rate): Has also been administered as a continuous infusion to avoid peaks and troughs associated with intermittent infusions in patients who require prolonged treatment periods. Use a smart infusion pump with small volume infusion capability. Refer to protocols for product selection and preparation details (Ref).

Administration: Pediatric

Parenteral: IV administration only; use administration sets/tubing provided by manufacturer (if provided). Adjust administration rate based on patient response.

Intermittent IV: Rate of administration should be determined by patient tolerability (maximum rates vary by product).

Advate: Infuse over ≤5 minutes; maximum infusion rate: 10 mL/minute.

Afstyla: Infuse up to a maximum infusion rate of 10 mL/minute.

Kogenate FS, Kovaltry: Infuse over 1 to 15 minutes.

Novoeight: Infuse slowly over 2 to 5 minutes.

Nuwiq: Infuse up to a maximum infusion rate of 4 mL/minute.

Recombinate: Infuse at a maximum rate of 5 mL/minute when reconstituted with 5 mL of SWFI.

Xyntha, Xyntha Solofuse: Infuse over several minutes. Do not admix or administer in same tubing as other medications.

Continuous IV infusion: Further dilution after initial reconstitution is unnecessary (Ref). Use a smart infusion pump with small volume infusion capability (Ref).

Use: Labeled Indications

Hemophilia A:

Control and prevention of bleeding episodes: Prevention and control of bleeding episodes in adults and children with hemophilia A.

Perioperative management: Surgical prophylaxis in adults and children with hemophilia A.

Routine prophylaxis to prevent or reduce the frequency of bleeding: Routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A.

Routine prophylaxis to prevent bleeding episodes and joint damage (Kogenate FS only): Routine prophylactic treatment to reduce the frequency of bleeding episodes and the risk of joint damage in children without preexisting joint damage.

Limitations of use: Not indicated for the treatment of von Willebrand disease.

Medication Safety Issues

Sound-alike/look-alike issues:

Factor VIII may be confused with Factor XIII

Other safety concerns:

Confusion may occur due to the omitting of “Factor VIII” from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Fitusiran: May increase thrombogenic effects of Clotting Factor Concentrates (CFCs) and Bypassing Agents (BPAs). Management: Stop CFC/BPA prophylaxis no later than 7 days after starting fitusiran. If bleeding occurs during the first 7 days of fitusiran, manage with the prior dosing regimen of CFC/BPA. If bleeding occurs after 7 days, use reduced CFC/BPA doses and frequencies. Risk D: Consider Therapy Modification

Pregnancy Considerations

Pregnant carriers of hemophilia A may have an increased bleeding risk following invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor VIII levels should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor VIII concentrations increase in pregnant patients, factor VIII replacement is recommended if concentrations are <50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor VIII concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If a replacement product is indicated, a recombinant product is preferred (NBDF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).

Breastfeeding Considerations

It is not known if antihemophilic factor (recombinant) is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Dietary Considerations

Some products may contain sodium.

Monitoring Parameters

Monitoring assay selection: For Advate, Afstyla, Kogenate FS, and Kovaltry, the World Federation of Hemophilia (WFH) recommends use of a one-stage or chromogenic factor VIII activity assay calibrated with a plasma standard traceable to a WHO international standard. For all other products, refer to the manufacturer's labeling for assay recommendations. Note: For patients receiving concomitant emicizumab therapy, emicizumab interferes with chromogenic factor VIII assays which use human factor IXa and factor X; use of chromogenic assays with bovine factor IXa and X is required to obtain reliable factor VIII activity when emicizumab is present (WFH [Srivastava 2020]).

Monitoring frequency: During treatment of an acute bleeding event or in the perioperative setting using intermittent bolus administration, factor VIII levels should be measured at baseline, and as peaks 15 to 30 minutes after infusion to assess target level achievement. Measurement of FVIII trough levels may aid in calculation of subsequent doses. Subsequent doses should ideally be based on the FVIII half-life and on the factor recovery of the individual patients. The frequency of peak factor VIII activity monitoring during active treatment depends on the indication, clinical response, and treatment day (WFH [Srivastava 2020]).

When administered as a continuous infusion, monitor factor VIII activity at baseline, peak factor VIII activity 15 to 30 minutes after initial bolus administration, and at least daily while on continuous infusion therapy. Frequently assess proper functioning of vascular access devices and infusion pumps for pump failure (WFH [Srivastava 2020]).

For long-term bleeding prophylaxis, trough factor VIII measurements should be obtained to tailor prophylaxis regimens, with the goal of achieving factor VIII troughs >3 to 5 units/dL; prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics.

Patients with low-titer inhibitors receiving factor VIII concentrate products should undergo frequent assessment of factor VIII levels and inhibitor titers to ensure response is maintained.

Additional monitoring considerations:

Heart rate and BP before and during IV administration, signs of hypersensitivity reactions, hemoglobin/hematocrit, and signs and symptoms of intravascular hemolysis.

For both intermittent bolus and continuous infusion administration, lower than expected factor VIII recovery or reduced half-life are early signs of inhibitor formation.

Reference Range

Classification of hemophilia; normal is defined as 100% factor VIII (WFH [Srivastava 2020]).

Severe: Factor level <1% of normal

Moderate: Factor level 1% to 5% of normal

Mild: Factor level >5% to <40% of normal

Mechanism of Action

Factor VIII replacement, necessary for clot formation and maintenance of hemostasis. It activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: V_ss: ~0.4 to 0.85 dL/kg.

Half-life elimination:

Advate: Children <12 years: 8.7 to 11.2 hours; Adolescents and Adults: 12 hours.

Afstyla: Children <12 years: 10.2 to 10.4 hours; Children ≥12 years and Adolescents: 14.3 hours; Adults: 14.2 hours.

Kogenate FS: Children: 10.7 hours; Adults: 13.7 to 14.6 hours.

Kovaltry: Children <12 years: ~12 hours; Children ≥12 years, Adolescents, and Adults: ~14 hours.

Novoeight: Children <12 years: 7.7 to 10 hours; Adolescents and Adults: 11 to 12 hours.

Nuwiq: Children ≤12 years: 11.9 to 13.1 hours; Adolescents and Adults: 17.1 hours.

Recombinate: Adults: 14.6 ± 4.9 hours.

Xyntha, Xyntha Solofuse: Children 3.7 to 5.8 years: 8.3 ± 2.7 hours; Adolescents 14 to 15 years: 6.9 ± 2.4 hours; Adults: 11 to 17 hours.

Zonovate [Canadian product]: Children ≤12 years: ~7.5 to 10 hours; Adolescents and Adults: ~11 to 12 hours.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Advate | Recombinate;
(AR) Argentina: Advate | Kogenate fs | Kovaltry;
(AT) Austria: Advate | Iblias | Kogenate | Kovaltry | Recombinate;
(AU) Australia: Advate | Kogenate | Recombinate;
(BE) Belgium: Advate | Helixate nexgen | Kogenate | Kovaltry | Recombinate;
(BG) Bulgaria: Advate | Kogenate | Kovaltry;
(BR) Brazil: Advate | Kovaltry;
(CH) Switzerland: Helixate M2V | Helixate nexgen | Kogenate SF | Kovaltry | Recombinate;
(CL) Chile: Kogenate;
(CO) Colombia: Advate | Kovaltry | Recombinate;
(CZ) Czech Republic: Advate | Helixate nexgen | Kovaltry | Recombinate;
(DE) Germany: Advate | Iblias | Kogenate | Kovaltry | Recombinate;
(EC) Ecuador: Kovaltry;
(EE) Estonia: Advate | Recombinate;
(EG) Egypt: Kogenate fs;
(ES) Spain: Advate | Helixate nexgen | Iblias | Kogenate | Kovaltry | Recombinate;
(FI) Finland: Advate | Helixate nexgen | Kogenate | Kovaltry | Recombinate;
(FR) France: Advate | Helixate nexgen | Kogenate | Kovaltry;
(GB) United Kingdom: Advate | Helixate nexgen | Kogenate | Recombinate;
(GR) Greece: Advate | Helixate nexgen | Kogenate | Kovaltry;
(HK) Hong Kong: Advate | Kogenate fs;
(HU) Hungary: Helixate nexgen | Kogenate | Kovaltry;
(ID) Indonesia: Kogenate;
(IE) Ireland: Advate | Helixate nexgen;
(IN) India: Recombinate;
(IS) Iceland: Helixate nexgen;
(IT) Italy: Advate | Kogenate | Kovaltry;
(JO) Jordan: Kogenate;
(JP) Japan: Advate | Kogenate | Kogenate fs | Recombinate;
(KR) Korea, Republic of: Advate | Kogenate fs | Recombinate;
(KW) Kuwait: Kogenate;
(LB) Lebanon: Kogenate | Recombinate;
(LT) Lithuania: Advate | Kogenate bayer | Kovaltry;
(LU) Luxembourg: Kogenate | Kovaltry;
(LV) Latvia: Advate | Kogenate | Recombinate;
(MA) Morocco: Kogenate;
(MX) Mexico: Advate | Kovaltry | Recombinate;
(MY) Malaysia: Advate | Kogenate fs;
(NL) Netherlands: Advate | Helixate nexgen | Iblias | Kogenate | Kovaltry | Recombinate;
(NO) Norway: Advate | Helixate nexgen | Kovaltry;
(NZ) New Zealand: Advate | Kogenate SF | Recombinate;
(PA) Panama: Kovaltry;
(PL) Poland: Kogenate bayer;
(PR) Puerto Rico: Advate | Kogenate fs | Kovaltry;
(PT) Portugal: Advate | Helixate nexgen | Kogenate | Recombinate;
(PY) Paraguay: Kovaltry;
(QA) Qatar: Advate | Afstyla | Kogenate FS | Kovaltry | NovoEight | Xyntha | Xyntha Solofuse;
(RO) Romania: Advate | Kogenate bayer | Kovaltry | Recombinate;
(RU) Russian Federation: Advate | Kogenate fs;
(SA) Saudi Arabia: Advate | Kogenate | Recombinate;
(SE) Sweden: Advate | Helixate nexgen | Kogenate bayer | Kovaltry | Recombinate;
(SG) Singapore: Advate | Kogenate fs;
(SI) Slovenia: Advate | Kovaltry;
(SK) Slovakia: Advate | Kogenate;
(SR) Suriname: Advate;
(TH) Thailand: Advate | Kogenate fs | Recombinate;
(TN) Tunisia: Advate | Kogenate fs;
(TR) Turkey: Advate | Kovaltry | Recombinate;
(TW) Taiwan: Advate | Kogenate | Kogenate fs | Kovaltry;
(UA) Ukraine: Advate | Kogenate fs | Recombinate;
(ZA) South Africa: Kogenate | Kovaltry

Abshire TC, Brackmann HH, Scharrer I, et al, “Sucrose Formulated Recombinant Human Antihemophilic Factor VIII is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. International Kogenate-FS Study Group,” Thromb Haemost, 2000, 83(6):811-6. [PubMed 10896230]
Advate (antihemophilic factor [recombinant]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.
Afstyla (antihemophilic factor [recombinant]) [prescribing information]. Kankakee, IL: CSL Behring LLC; June 2023.
Afstyla (antihemophilic factor [recombinant]) [prescribing information]. Kankakee, IL: CSL Behring LLC; December 2019.
Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
Batorova A, Holme P, Gringeri A, et al; European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. Haemophilia. 2012;18(5):753-759. doi:10.1111/j.1365-2516.2012.02810.x [PubMed 22530687]
Batorova A, Martinowitz U. Continuous infusion of coagulation factors. Haemophilia. 2002;8(3):170-177. doi:10.1046/j.1365-2516.2002.00635.x [PubMed 12010406]
Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol. 2000;110(3):715-720. [PubMed 10997985]
Bidlingmaier C, Deml MM, Kurnik K. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections. Haemophilia. 2006;12(3):212-217. doi:10.1111/j.1365-2516.2006.01217.x [PubMed 16643203]
Bray GL, Gomperts ED, Courter S, et al, “A Multicenter Study of Recombinant Factor VIII (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A. The Recombinate Study Group,” Blood, 1994, 83(9):2428-35. [PubMed 8167332]
Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm [PubMed 6423951]
Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17(1):2-10. [PubMed 20731726]
Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia. 2018;24(1):24-32. doi:10.1111/hae.13331 [PubMed 28873263]
Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
Kelly KM, Butler RB, Farace L, et al, “Superior In Vivo Response of Recombinant Factor VIII Concentrate in Children With Hemophilia A,” J Pediatr, 1997, 130(4):537-40. [PubMed 9108849]
Kogenate FS (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; December 2019.
Kogenate FS (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; May 2016.
Kogenate FS with Bio-Set (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; May 2016.
Kogenate FS with Vial Adapter (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; May 2016.
Kovaltry (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; December 2022.
Kovaltry (antihemophilic factor [recombinant]) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; March 2023.
Liesner RJ, “Prophylaxis in Haemophilic Children,” Blood Coagul Fibrinolysis, 1997, 8(Suppl 1):S7-10. [PubMed 9351529]
Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
Lusher JM, “Transfusion Therapy in Congenital Coagulopathies,” Hematol Oncol Clin North Am, 1994, 8(6):1167-80. [PubMed 7860443]
Manucci PM, “Impact of Recombinant Factor VIII on Hemophilia Care,” Vox Sang, 1994, 67(Suppl 3):49-52. [PubMed 7975511]
Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol. 1992;82(4):729-734. [PubMed 1482660]
National Bleeding Disorders Foundation (NBDF). Medical and Scientific Advisory Council (MASAC) guidelines for emergency department management of individuals with hemophilia and other bleeding disorders (MASAC document 257). https://www.bleeding.org/sites/default/files/document/files/257.pdf. Published December 5, 2019. Accessed July 15, 2024.
National Bleeding Disorders Foundation (NBDF). MASAC recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). 2007.
National Bleeding Disorders Foundation (NBDF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). Published September 17, 2017. Accessed June 7, 2018.
Nilsson IM, Berntorp E, Lofqvist T, et al, “Twenty-five Years' Experience of Prophylactic Treatment in Severe Haemophilia A and B,” J Intern Med, 1992, 232(1):25-32. [PubMed 1640190]
Novoeight (antihemophilic factor [recombinant]) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; July 2020.
Nuwiq (antihemophilic factor [recombinant]) [prescribing information]. Paramus, NJ: Octapharma USA Inc; December 2024.
Nuwiq (antihemophilic factor [recombinant]) [prescribing information]. Paramus, NJ: Octapharma USA Inc; September 2020.
Nuwiq (antihemophilic factor [recombinant]) [prescribing information]. Hoboken, NJ: Octapharma; July 2017.
Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). BJOG. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592. [PubMed 28447403]
Poon MC, Card R. Hemophilia management in transfusion medicine. Transfus Apher Sci. 2012;46(3):299-307. doi:10.1016/j.transci.2012.03.020 [PubMed 22503305]
Prelog T, Dolničar MB, Kitanovski L. Low-dose continuous infusion of factor VIII in patients with haemophilia A. Blood Transfus. 2016;14(5):474-480. [PubMed 26674820]
Qfitlia (fitusiran) [prescribing information]. Cambridge, MA: Genzyme Corporation; March 2025.
Recombinate (antihemophilic factor [recombinant]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.
Refer to manufacturer’s labeling.
Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia. 1995;1(suppl 1):8-13. doi:10.1111/j.1365-2516.1995.tb00104.x
Rossbach HC. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A. Vasc Health Risk Manag. 2010;6:59-68. [PubMed 20234780]
Scharrer I, Bray GL, and Neutzling O, “Incidence of Inhibitors in Haemophilia A Patients - A Review of Recent Studies of Recombinant and Plasma-Derived Factor VIII Concentrates,” Haemophilia, 1999, 5(3):145-54. [PubMed 10444280]
Schwartz RS, Abildgaard CF, Aledort LM, et al, “Human Recombinant DNA-Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. Recombinant Factor VIII Study Group,” N Engl J Med, 1990, 323(26):1800-5. [PubMed 2123300]
Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
Shord SS and Lindley CM, “Coagulation Products and Their Uses,” Am J Health Syst Pharm, 2000, 57(15):1403-20. [PubMed 10938981]
Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046 [PubMed 32744769]
Suzuki N, Hirakawa A, Kishimoto M, et al. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. Haemophilia. 2017;23(2):215-221. doi:10.1111/hae.13082 [PubMed 27704637]
Varon D, Martinowitz U. Continuous infusion therapy in haemophilia. Haemophilia. 1998;4(4):431-435. [PubMed 9873771]
White GC, Rosendaal F, Aledort LM, et al, “Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis,” Thromb Haemost, 2001, 85(3):560. [PubMed 11307831]
Xyntha (antihemophilic factor [recombinant]) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; July 2022.
Xyntha Solofuse (antihemophilic factor [recombinant]) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; July 2022.
Zonovate (antihemophilic factor [recombinant]) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; April 2021.

Topic 9723 Version 385.0

خرید پکیج

Factor VIII, recombinant human: Drug information